Dose-Finding Designs Based on the Continual Reassessment Method

[1]  J O'Quigley,et al.  Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method , 2011, Statistics in medicine.

[2]  Shyamal D Peddada,et al.  Designs for Single‐ or Multiple‐Agent Phase I Trials , 2004, Biometrics.

[3]  Shing M. Lee,et al.  Model calibration in the continual reassessment method , 2009, Clinical trials.

[4]  T A Gooley,et al.  Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. , 1994, Controlled clinical trials.

[5]  Jianfen Shu,et al.  Dose‐escalation designs in oncology: ADEPT and the CRM , 2008, Statistics in medicine.

[6]  John O'Quigley,et al.  Consistency of continual reassessment method under model misspecification , 1996 .

[7]  Alan E. Gelfand,et al.  Model choice: A minimum posterior predictive loss approach , 1998, AISTATS.

[8]  L. Natarajan,et al.  Interval estimates of the probability of toxicity at the maximum tolerated dose for small samples , 2003, Statistics in medicine.

[9]  J Whitehead,et al.  Bayesian decision procedures based on logistic regression models for dose-finding studies. , 1998, Journal of biopharmaceutical statistics.

[10]  L V Rubinstein,et al.  A comparison of two phase I trial designs. , 1994, Statistics in medicine.

[11]  J B Greenhouse,et al.  Bayesian methods for phase I clinical trials. , 1992, Statistics in medicine.

[12]  C. Ahn,et al.  An evaluation of phase I cancer clinical trial designs , 1998 .

[13]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[14]  Ying Yuan,et al.  Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials , 2009 .

[15]  S. Møller,et al.  An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. , 1995, Statistics in medicine.

[16]  S. Goodman,et al.  Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.

[17]  S Zacks,et al.  Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[18]  Elizabeth Garrett-Mayer,et al.  The continual reassessment method for dose-finding studies: a tutorial , 2006, Clinical trials.

[19]  J O'Quigley,et al.  Another look at two phase I clinical trial designs. , 1999, Statistics in medicine.

[20]  John O'Quigley,et al.  Non-parametric optimal design in dose finding studies. , 2002, Biostatistics.

[21]  Thomas M Braun,et al.  The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes. , 2002, Controlled clinical trials.

[22]  John O'Quigley,et al.  Continual reassessment designs with early termination. , 2002, Biostatistics.

[23]  John O'Quigley,et al.  Continual Reassessment Method for Ordered Groups , 2003, Biometrics.

[24]  S. Piantadosi,et al.  Improved designs for dose escalation studies using pharmacokinetic measurements. , 1996, Statistics in medicine.

[25]  Ethan Reiner,et al.  A stopping rule for the continual reassessment method , 1998 .

[26]  Weichung Joe Shih,et al.  Unifying CRM and EWOC designs for phase I cancer clinical trials , 2009 .

[27]  Sarah Zohar,et al.  Incorporating lower grade toxicity information into dose finding designs , 2011, Clinical trials.

[28]  J O'Quigley,et al.  Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer. , 1992, Biometrics.

[29]  John O'Quigley,et al.  Dose-finding design for multi-drug combinations , 2011, Clinical trials.

[30]  S Chevret,et al.  The continual reassessment method in cancer phase I clinical trials: a simulation study. , 1993, Statistics in medicine.

[31]  John O'Quigley,et al.  Theoretical study of the continual reassessment method , 2006 .

[32]  Ethan Reiner,et al.  Operating characteristics of the standard phase I clinical trial design , 1999 .

[33]  Ying Kuen Cheung,et al.  A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method , 2002, Biometrics.

[34]  J O'Quigley,et al.  Two-sample continual reassessment method. , 1999, Journal of biopharmaceutical statistics.

[35]  S. Chevret,et al.  Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. , 1991, Statistics in medicine.

[36]  B E Storer,et al.  Small-sample confidence sets for the MTD in a phase I clinical trial. , 1993, Biometrics.

[37]  S Zohar,et al.  The continual reassessment method: comparison of Bayesian stopping rules for dose‐ranging studies , 2001, Statistics in medicine.

[38]  Sarah Zohar,et al.  Retrospective Robustness of the Continual Reassessment Method , 2010, Journal of biopharmaceutical statistics.

[39]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.

[40]  Alexia Iasonos,et al.  A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies , 2008, Clinical trials.

[41]  J. O'Quigley,et al.  Dynamic calibration of pharmacokinetic parameters in dose-finding studies. , 2010, Biostatistics.

[42]  J O'Quigley,et al.  Continual reassessment method: a likelihood approach. , 1996, Biometrics.

[43]  A. Oza,et al.  Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  H. Sung,et al.  Dose‐Finding Based on Feasibility and Toxicity in T‐cell Infusion Trials , 2001, Biometrics.

[45]  J O'Quigley,et al.  Dose‐Finding Designs for HIV Studies , 2001, Biometrics.

[46]  S. Piantadosi,et al.  Practical implementation of a modified continual reassessment method for dose-finding trials , 1998, Cancer Chemotherapy and Pharmacology.